🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

CLBT stock soars to all-time high, reaching $17.48

Published 13/09/2024, 19:42
© Shlomi Yosef, Cellebrite PR
CLBT
-

Cellebrite DI Ltd. (CLBT), a global leader in digital intelligence solutions for the law enforcement and intelligence communities, has seen its stock reach an all-time high of $17.48. This milestone reflects a significant surge in investor confidence and market performance for the company. Over the past year, the stock has witnessed an impressive ascent, with TWC Tech Holdings II ORD, the parent organization, reporting a 1-year change of 139.56%. This remarkable growth trajectory underscores the increasing demand for digital intelligence tools and the company's expanding footprint in the sector. Investors are closely monitoring CLBT's progress as it continues to innovate and capture market share in this rapidly evolving industry.


In other recent news, Cellebrite reported a substantial year-over-year growth in its Q2 earnings call. The company saw a 26% increase in Annual Recurring Revenue (ARR) to $346 million and a 25% rise in revenue to $95.7 million, primarily driven by the robust performance of its subscription software. These developments were underscored by the strategic formation of Cellebrite Federal Solutions and an emphasis on AI-powered capabilities.


The company also adjusted its full-year outlook for 2024, anticipating strong demand from U.S. federal agency customers. Cellebrite projects Q3 adjusted EBITDA to range between $25 million and $29 million and expects to upgrade 15% of its installed base to Inseyets in 2024.


However, it was noted that the company's net retention rate has slightly decreased. In terms of future expectations, Cellebrite predicts the federal sector to double in size within the next three to five years. The partnership with Relativity is still in its early stages, and the company is cautious about updating targets before proper execution.


InvestingPro Insights


Cellebrite DI Ltd. (CLBT) not only has hit a new stock price peak but also exhibits financial metrics that may interest investors looking for growth potential. With a market capitalization of $3.63 billion, the company has shown a robust revenue growth of 23.46% over the last twelve months as of Q2 2024. This is complemented by an even higher quarterly revenue growth rate of 24.82%, indicating a strong upward trend in the company's sales. Impressively, Cellebrite has maintained a gross profit margin of 84.19%, which is reflective of its efficient operations and cost management.
InvestingPro Tips suggest that Cellebrite is expected to see net income growth this year, with analysts having revised their earnings upwards for the upcoming period. This aligns with the company's recent performance, where it has achieved a high return over the last year, with a year-to-date price total return of 95.84%. Additionally, the company is trading near its 52-week high, at 99.8% of this value, and analysts predict that Cellebrite will be profitable this year.
For investors seeking more in-depth analysis, there are over 16 additional InvestingPro Tips available at https://www.investing.com/pro/CLBT, which provide further insights into Cellebrite's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.